FINAL_EHA 2024 RWE Summary.pdfRWE Studies from EHA 2024: Updates on the Treatment of CLL
EHA 2024 Summary (1).pdfUpdates from EHA 2024: Key Data on the Treatment of CLL
00_ASH2023_MtgReport_Dec_2023_01-05.pdfHighlights from ASH 2023: Updates in the Treatment of CLL
Highlights from CCOLD 2023: Updates in the Treatment of CLL
00_ASH2022_MtgReport_Jan18_2022.pdfUpdates from ASH 2022: Updates on the treatment of CLL
01_ASH2021_Jan09_22 (1).pdfHighlights from ASH 2021: Updates on the treatment of CLL
ASCO2021_Summary_Final.pdfUpdates from the ASCO/EHA 2021: Updates on the treatment of CLL
ASH_Report_Jan15_21.pdfUpdates from ASH 2020: Practice-changing studies in CLL
Highlights from ASCO 2020: Updates on the treatment of CLL
Updates from the ASH 2019: Practice-changing studies in treatment-naïve CLL
Updates from ASCO/EHA 2019: A Canadian perspective on high-risk cytogenetics in MM
Updates from ASH 2017: practice-changing studies in relapsed and refractory MCL
